Top

Published in:

01-01-2021 | NSCLC | Original Article

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer

Authors: Jiexia Zhang, Ningning Zhou, Anqi Lin, Peng Luo, Xin Chen, Huojin Deng, Shijun Kang, Linlang Guo, Weiliang Zhu, Jian Zhang

Published in: Cancer Immunology, Immunotherapy | Issue 1/2021

Abstract

To date, immunotherapy has opened a new chapter in the treatment of lung cancer. Precise biomarkers can help to screen subpopulations of lung cancer to provide the best treatment. Multiple studies suggest that specific gene mutations may be predictive markers in guiding non-small cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) treatment. A published immunotherapy cohort with mutational and survival data for 350 NSCLC patients was used. First, the mutational data of the immunotherapy cohort were used to identify gene mutations related to the prognosis of ICI therapy. The immunotherapy cohort and TCGA-NSCLC cohort were further studied to elucidate the relationships between specific gene mutations and tumor immunogenicity, antitumor immune response capabilities, and immune cell and mutation counts in the DNA damage response (DDR) pathway. In the immunotherapy cohort (N = 350), ZFHX3 mutations were an independent predictive biomarker for NSCLC patients receiving ICI treatment. Significant differences were observed between ZFHX3-mutant (ZFHX3-MT) and ZFHX3-wild type (ZFHX3-WT) patients regarding the overall survival (OS) time (P < 0.001, HR = 0.26, 95% Cl 0.17–0.41). ZFHX3-MT is significantly associated with higher tumor mutation burden (TMB) and neoantigen load (NAL), and ZFHX3-MT positively correlates with known immunotherapy response biomarkers, including T-cell infiltration, immune-related gene expression, and mutation counts in the DDR pathway in NSCLC. ZFHX3-MT is closely related to longer OS in NSCLC patients treated with ICIs, suggesting that ZFHX3 mutations be used as a novel predictive marker in guiding NSCLC ICI treatment.

Available only for authorised users

Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. JAMA Oncol 3:524. https://doi.org/10.1001/jamaoncol.2016.5688CrossRefPubMed

Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824CrossRefPubMed

Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150CrossRefPubMedPubMedCentral

Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aad7118CrossRefPubMedPubMedCentral

Wang S, He Z, Wang X et al (2019) Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. https://doi.org/10.7554/eLife.49020CrossRefPubMedPubMedCentral

Boeri M, Milione M, Proto C et al (2019) Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: A prospective study. Clin Cancer Res 25:2166–2173CrossRefPubMedPubMedCentral

Cristescu R, Mogg R, Ayers M et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. https://doi.org/10.1126/science.aar3593CrossRefPubMedPubMedCentral

Riaz N, Havel JJ, Kendall SM et al (2016) Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat Genet 48:1327–1329. https://doi.org/10.1038/ng.3677CrossRefPubMedPubMedCentral

Wang F, Zhao Q, Wang YN et al (2019) Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 5:1504–1506CrossRefPubMedPubMedCentral

10.

Wu HX, Chen YX, Wang ZX et al (2019) Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. J Immunother Cancer 7:264. https://doi.org/10.1186/s40425-019-0737-3CrossRefPubMedPubMedCentral

11.

Dong Z-Y, Zhong W-Z, Zhang X-C et al (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23:3012–3024. https://doi.org/10.1158/1078-0432.CCR-16-2554CrossRefPubMed

12.

Ji M, Liu Y, Li Q et al (2016) PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 17:407–413. https://doi.org/10.1080/15384047.2016.1156256CrossRefPubMedPubMedCentral

13.

Spigel DR, Schrock AB, Fabrizio D et al (2016) Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol 34:9017–9017. https://doi.org/10.1200/jco.2016.34.15_suppl.9017CrossRef

14.

Lin A, Wei T, Meng H et al (2019) Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer 18:139CrossRefPubMedPubMedCentral

15.

Wang J, Wang Z, Zhao J et al (2018) Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-18-1814CrossRefPubMedPubMedCentral

16.

Teo MY, Seier K, Ostrovnaya I et al (2018) Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 36:1685–1694. https://doi.org/10.1200/JCO.2017.75.7740CrossRefPubMedPubMedCentral

17.

Samstein RM, Lee C-H, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202–206. https://doi.org/10.1038/s41588-018-0312-8CrossRefPubMedPubMedCentral

18.

Colaprico A, Silva TC, Olsen C et al (2016) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44:e71–e71. https://doi.org/10.1093/nar/gkv1507CrossRefPubMed

19.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095CrossRefPubMed

20.

Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33:843–852.e4. https://doi.org/10.1016/j.ccell.2018.03.018CrossRefPubMedPubMedCentral

21.

Newman AM, Liu CL, Green MR et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457. https://doi.org/10.1038/nmeth.3337CrossRefPubMedPubMedCentral

22.

Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48:812–830.e14. https://doi.org/10.1016/j.immuni.2018.03.023CrossRefPubMedPubMedCentral

23.

Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https://doi.org/10.1186/s13073-017-0424-2CrossRefPubMedPubMedCentral

24.

Yu G, Wang L-G, Han Y, He Q-Y (2012) cluster profiler: an R package for comparing biological themes among gene clusters. Omi A J Integr Biol 16:284–287. https://doi.org/10.1089/omi.2011.0118CrossRef

25.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102:15545–15550. https://doi.org/10.1073/pnas.0506580102CrossRefPubMedPubMedCentral

26.

Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32:2847–2849. https://doi.org/10.1093/bioinformatics/btw313CrossRefPubMed

27.

Luo P, Lin A, Li K et al (2019) DDR pathway alteration, tumor mutation burden, and cisplatin sensitivity in small cell lung cancer: difference detected by whole exome and targeted gene sequencing. J Thorac Oncol 14:e276–e279CrossRefPubMed

28.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/NEJMoa1500596CrossRefPubMedPubMedCentral

29.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. https://doi.org/10.1126/science.aaa1348CrossRefPubMedPubMedCentral

30.

Gao J, Shi LZ, Zhao H et al (2016) Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397–404.e9. https://doi.org/10.1016/j.cell.2016.08.069CrossRefPubMedPubMedCentral

31.

Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819–829. https://doi.org/10.1056/NEJMoa1604958CrossRefPubMedPubMedCentral

32.

Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin Cancer Res 22:4585–4593. https://doi.org/10.1158/1078-0432.CCR-15-3101CrossRefPubMedPubMedCentral

33.

Peng W, Chen JQ, Liu C et al (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6:202–216. https://doi.org/10.1158/2159-8290.CD-15-0283CrossRefPubMed

34.

Hu Q, Zhang B, Chen R et al (2019) ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis 8:28. https://doi.org/10.1038/s41389-019-0138-yCrossRefPubMedPubMedCentral

35.

Fu C, An N, Liu J et al (2020) The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells. J Biol Chem 295:7060–7074. https://doi.org/10.1074/jbc.RA119.012131CrossRefPubMedPubMedCentral

36.

Jung C-G, Kim H-J, Kawaguchi M et al (2005) Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation. Development 132:5137–5145. https://doi.org/10.1242/dev.02098CrossRefPubMed

37.

Kataoka H, Miura Y, Joh T et al (2001) Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. Oncogene 20:869–873. https://doi.org/10.1038/sj.onc.1204160CrossRefPubMed

38.

Zaw KTT, Sato N, Ikeda S et al (2017) Association of ZFHX3 gene variation with atrial fibrillation, cerebral infarction, and lung thromboembolism: An autopsy study. J Cardiol 70:180–184. https://doi.org/10.1016/j.jjcc.2016.11.005CrossRefPubMed

39.

Grasso CS, Wu Y-M, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243. https://doi.org/10.1038/nature11125CrossRefPubMedPubMedCentral

40.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD (2015) Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125:3413–3421. https://doi.org/10.1172/JCI80008CrossRefPubMedPubMedCentral

41.

Mellman I, Steinman RM (2001) Dendritic Cells. Cell 106:255–258. https://doi.org/10.1016/S0092-8674(01)00449-4CrossRefPubMed

42.

Spitzer MH, Carmi Y, Reticker-Flynn NE et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168:487–502.e15. https://doi.org/10.1016/j.cell.2016.12.022CrossRefPubMedPubMedCentral

43.

Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930–2940. https://doi.org/10.1172/JCI91190CrossRefPubMedPubMedCentral

44.

Jiang P, Gu S, Pan D et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550–1558. https://doi.org/10.1038/s41591-018-0136-1CrossRefPubMedPubMedCentral

45.

Peng D, Kryczek I, Nagarsheth N et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249–253. https://doi.org/10.1038/nature15520CrossRefPubMedPubMedCentral

46.

Overacre-Delgoffe AE, Chikina M, Dadey RE et al (2017) Interferon-γ drives treg fragility to promote anti-tumor immunity. Cell 169:1130–1141.e11. https://doi.org/10.1016/j.cell.2017.05.005CrossRefPubMedPubMedCentral

47.

Swamy M, Beck-Garcia K, Beck-Garcia E et al (2016) A cholesterol-based allostery model of t cell receptor phosphorylation. Immunity 44:1091–1101. https://doi.org/10.1016/j.immuni.2016.04.011CrossRefPubMed

48.

Wang F, Beck-García K, Zorzin C et al (2016) Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. Nat Immunol 17:844–850. https://doi.org/10.1038/ni.3462CrossRefPubMedPubMedCentral

49.

Baek AE, Yu YRA, He S et al (2017) The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun 8:864. https://doi.org/10.1038/s41467-017-00910-zCrossRefPubMedPubMedCentral

50.

Ma X, Bi E, Lu Y et al (2019) Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab 30:143–156.e5. https://doi.org/10.1016/j.cmet.2019.04.002CrossRefPubMedPubMedCentral

51.

Lambrechts D, Wauters E, Boeckx B et al (2018) Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med 24:1277–1289. https://doi.org/10.1038/s41591-018-0096-5CrossRefPubMed

Title: ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
Authors: Jiexia Zhang
Ningning Zhou
Anqi Lin
Peng Luo
Xin Chen
Huojin Deng
Shijun Kang
Linlang Guo
Weiliang Zhu
Jian Zhang
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Checkpoint Inhibitors
Biomarkers
Published in: Cancer Immunology, Immunotherapy / Issue 1/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02668-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis

Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation

Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer

Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

Keynote webinar | Spotlight on antibody–drug conjugates in cancer